PMID- 28181819
OWN - NLM
STAT- MEDLINE
DCOM- 20170414
LR  - 20181202
IS  - 1748-880X (Electronic)
IS  - 0007-1285 (Print)
IS  - 0007-1285 (Linking)
VI  - 90
IP  - 1072
DP  - 2017 Apr
TI  - Dose escalation study with respiratory-gated carbon-ion scanning radiotherapy 
      using a simultaneous integrated boost for pancreatic cancer: simulation with 
      four-dimensional computed tomography.
PG  - 20160790
LID - 10.1259/bjr.20160790 [doi]
LID - 20160790
AB  - OBJECTIVE: Pancreatic cancer is a difficult to treat disease with a persistently 
      high mortality rate. We evaluated dose distribution simulation with 
      respiratory-gated carbon-ion pencil beam scanning (C-PBS) with a simultaneous 
      integrated boost (SIB) to increase tumour dose, sparing organs at risk (OARs). 
      METHODS: Using four-dimensional CT data of 12 patients, we delineated gross 
      tumour volume and two clinical target volumes (CTVs). To consider beam range 
      intrafractional uncertainty, we calculated field-specific target volumes, from 
      which two planning target volumes (PTVs) were generated. PTV1 would receive a 
      planned dose of 55.2 Gy [relative biological effectiveness (RBE)-weighted 
      absorbed dose] in 12 fractions, and PTV2 would receive an SIB dose up to 67.2 Gy 
      (RBE). Dose assessments were conducted with regard to the targets and OARs. 
      RESULTS: CTV2 dose covering 95% of the volume (D(95%)) increased from 
      50.3 +/- 5.1 Gy (RBE) to 62.5 +/- 3.5 Gy (RBE) for a planned dose from 55.2 Gy (RBE) 
      to 67.2 Gy (RBE). For 4 of 12 patients with a distance of >/=5 mm between the 
      tumour and the gastrointestinal tract, CTV2 D(95%) was >/=95% of planned dose at 
      all dose levels. CONCLUSION: We quantified dose escalation with respiratory-gated 
      C-PBS using SIB for pancreatic cancer and revealed that OAR dose was not affected 
      to the same degree as the tumour dose. Advances in knowledge: A simulation study 
      on respiratory-gated C-PBS with SIB for pancreatic cancer was performed. The 
      results indicated the feasibility of dose escalation for pancreatic cancer, which 
      should be confirmed in clinical trials.
FAU - Kawashiro, Shohei
AU  - Kawashiro S
AD  - 1 Hospital of the National Institute of Radiological Sciences, National 
      Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
AD  - 2 Department of Radiation Oncology, Faculty of Medicine, Yamagata University, 
      Yamagata, Japan.
FAU - Mori, Shinichiro
AU  - Mori S
AD  - 1 Hospital of the National Institute of Radiological Sciences, National 
      Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
FAU - Yamada, Shigeru
AU  - Yamada S
AD  - 1 Hospital of the National Institute of Radiological Sciences, National 
      Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
FAU - Miki, Kentaro
AU  - Miki K
AD  - 1 Hospital of the National Institute of Radiological Sciences, National 
      Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
FAU - Nemoto, Kenji
AU  - Nemoto K
AD  - 2 Department of Radiation Oncology, Faculty of Medicine, Yamagata University, 
      Yamagata, Japan.
FAU - Tsuji, Hiroshi
AU  - Tsuji H
AD  - 1 Hospital of the National Institute of Radiological Sciences, National 
      Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
FAU - Kamada, Tadashi
AU  - Kamada T
AD  - 1 Hospital of the National Institute of Radiological Sciences, National 
      Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
LA  - eng
PT  - Journal Article
DEP - 20170209
PL  - England
TA  - Br J Radiol
JT  - The British journal of radiology
JID - 0373125
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Dose Fractionation, Radiation
MH  - Female
MH  - Four-Dimensional Computed Tomography/*methods
MH  - Heavy Ion Radiotherapy/*methods
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pancreatic Neoplasms/*diagnostic imaging/*radiotherapy
MH  - *Radiotherapy Dosage
MH  - Treatment Outcome
PMC - PMC5605067
EDAT- 2017/02/10 06:00
MHDA- 2017/04/15 06:00
PMCR- 2018/04/01
CRDT- 2017/02/10 06:00
PHST- 2017/02/10 06:00 [pubmed]
PHST- 2017/04/15 06:00 [medline]
PHST- 2017/02/10 06:00 [entrez]
PHST- 2018/04/01 00:00 [pmc-release]
AID - 10.1259/bjr.20160790 [doi]
PST - ppublish
SO  - Br J Radiol. 2017 Apr;90(1072):20160790. doi: 10.1259/bjr.20160790. Epub 2017 Feb 
      9.